���景与受体作用机制 — Reference Sheet

By Editorial Desk · published 2026-01-13 · last reviewed 2026-02-02 · Guide

Pentapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.

背景与受体作用机制

Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。

Receptor Mechanism and Secretagogue Action

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

Ipamorelin at a glance

Ipamorelin Background and Mechanism

Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.

Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.

Related pages on this site

• Connected toolkit
• Verified comparison
• Efficient overview
• Verified digest
• Modular briefing
• Measured summary
• Structured toolkit
• Lightweight workbook

Ipamorelin Background and Pharmacology

At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.

Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.

Ipamorelin Background and Receptor Pharmacology

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.

Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.

Analytical Characterization and Storage Practice

Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.

Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.

Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.

Further detail

=== New Zealand === Beak trimming, officially known as 'beak tipping' in law, is legal but regulated in New Zealand. The Layer Hens Code of Welfare (last updated 1 October 2018) notes that the National Animal Welfare Advisory Committee (NAWAC) "encourages the industry to develop management systems to protect against all forms of injurious pecking without the need for beak tipping". The Code recommends that "[a]lternative strategies for managing injurious (feather) pecking that minimise the need for beak tipping should be employed e.g. use and availability of different foraging resources." In case that beak tipping is deemed necessary, however, it requires competent trained operators, must be carried out within 3 days of hatching (except in emergencies under veterinary supervision) and may not remove more than one-quarter of the upper or lower beaks.

Classification and Evolution Regulation, Development, and Molecular Diversity Aquatic Environments and Populations Ecology and Biodiversity Management History of Earth Men, Nature, and Societies, and Prehistory The diffusion departments are:

Depending on the column size, CIM monolithic columns are primarily used for the purification or analysis of large biomolecules which are being used for cancer gene therapy, treatment of viral infectious diseases and treatment of genetic diseases. Some types of molecules that can be successfully purified using CIM columns are pDNA, IgM, inter-alpha inhibitors, virus like particles, and diverse viruses; adenoviruses, bacteriophages, feline calicivirus, hepatitis A, lentivirus, influenza A and B, rabies virus, rotavirus, tomato and pepino mosaic virus. Since 2004, BIA Separations has organized and hosted the Monolith Summer School and Symposium (MSS) which takes place every 2 years. MSS was established as there were no dedicated conferences to this technology and to bring together the top international scientists and researchers in the area of monolith chromatography to share their experiences and innovative applications. BIA Separations home page Monolith Events

The orthologues and homologues of TMEM261 are limited to vertebrates, its oldest homologue dates to that of the cartilaginous fishes which diverged from Homo sapiens 462.5 million years ago. The protein primary structure of TMEM261 shows higher overall conservation in mammals, however high conservation of the domain of unknown function (DUF4536) to the C-terminus region is seen in all orthologues, including distant homologues. The protein structure of TMEM261 shows conservation across most orthologues. TMEM261 has no known paralogs. PubMed NCBI gene record GeneCards UCSC Genome Browser Expasy Bioinformatics Resource Portal SDSC Biology Workbench Uniprot HUGO Archived 2015-09-24 at the Wayback Machine

Sources: en.wikipedia.org

Background from the literature

StreptomeDB, a directory of Streptomyces isolates, contains over 2400 compounds isolated from more than 1900 strains. Streptomyces hygroscopicus and Streptomyces viridochromeogenes produce the herbicide bialaphos. Expansion of Streptomyces screenings have included endophytes, extremophiles, and marine varieties. A recent screening of TCM extracts revealed a Streptomyces that produces a number of antitubercular pluramycins. Wailupemycins are bio-active pyrones isolated from marine Streptomyces. Mayamycin has been shown to have cytotoxic properties. Germicidin are a group of four compounds that act as autoregulatory inhibitors of spore germination. StreptomeDB Antibiotics and Streptomyces : the future of antibiotic discovery Bioprospecting for Microbial Endophytes and Their Natural Products - 2003

== Applications == Owing to its scarcity, high price and radioactivity, 227Ac currently has no significant industrial use, but 225Ac is currently being studied for use in cancer treatments such as targeted alpha therapies. 227Ac is highly radioactive and was therefore studied for use as an active element of radioisotope thermoelectric generators, for example, in spacecraft. The oxide of 227Ac pressed with beryllium is also an efficient neutron source with the activity exceeding that of the standard americium-beryllium and radium-beryllium pairs. In all those applications, 227Ac (a beta source) is merely a progenitor which generates alpha-emitting isotopes upon its decay. Beryllium captures alpha particles and emits neutrons owing to its large cross-section for the (α,n) nuclear reaction:

=== Names === Oxitriptan is the generic name of the drug and its INNTooltip International Nonproprietary Name. Brand names of oxitriptan include Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum.

=== U.S. license to sell Venezuelan oil to Cuba === On 25 February, the United States emitted a license allowing companies to resell Venezuelan oil to Cuba's private sector. The U.S. Treasury Department indicated that the exchange must "support the Cuban people, including the private sector".

== Diagnosis == There are two types of cystocele. The first is distension. This is thought to be due to the overstretching of the vaginal wall and is most often associated with aging, menopause and vaginal delivery. It can be observed when the rugae are less visible or absent. The second type is displacement. Displacement is the detachment or abnormal elongation of supportive tissue. The initial assessment of cystocele can include a pelvic exam to evaluate leakage of urine when the women is asked to bear down or give a strong cough (Valsalva maneuver), and the anterior vaginal wall measured and evaluated for the appearance of a cystocele. If a woman has difficulty emptying her bladder, the clinician may measure the amount of urine left in the woman's bladder after she urinates called the postvoid residual. This is measured by ultrasound. A voiding cystourethrogram involves taking X-rays of the bladder during urination. This X-ray shows the shape of the bladder and lets the doctor see any problems that might block the normal flow of urine. A urine culture and sensitivity test will assess the presence of a urinary tract infection that may be related to urinary retention. Other tests may be needed to find or rule out problems in other parts of the urinary system. Differential diagnosis will be improved by identifying possible inflammation of the Skene's glands and Bartholin glands.

Sources: en.wikipedia.org

Frequently asked questions